---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-088792"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2025-09-18T23:59:59+00:00"
generated_at: "2026-05-17T06:19:25.861196+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nektar Phase 2b rezpegaldesleukin meets primary endpoint; EASI-75 66% vs 34% placebo at week 16

## Summary
- All three rezpegaldesleukin dose arms met primary endpoint of mean % EASI improvement at week 16 (p<0.001 vs placebo).
- High dose (24 µg/kg q2w) achieved statistical significance on EASI-75 (66% vs 34%), vIGA-AD 0/1 (19% vs 8%), and Itch NRS (42% vs 16%) at week 16.
- Placebo crossover to high dose showed deepening response: EASI-75 62% and vIGA-AD 0/1 38% at week 24.
- Safety consistent with prior data; most common AE mild injection site reactions; one death in escape arm assessed unrelated.
- Next milestones: maintenance data Q1 2026; alopecia areata data Dec 2025; Phase 3 planning underway.

## SEC filing metadata
- accession: 0001213900-25-088792
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2025-09-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390025088792/0001213900-25-088792-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390025088792/ea0257842-8k_nektar.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-088792
- JSON: https://secwatch.observer/filing/0001213900-25-088792.json
- Plain text: https://secwatch.observer/filing/0001213900-25-088792.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.